FIG 1.

Differential impact of HDACi in immortalized versus primary human cells. (A to C) The viability of TZM-bl cells (A) and primary human cells (B and C) was assessed by flow cytometry after the cells were pulsed with either romidepsin or panobinostat for 8 or 18 h and then incubated for an additional 24 or 48 h, as indicated in each subpanel. Panel A presents compiled results from (two) experiments performed in triplicate. Panels B and C present compiled data for PBMCs and CD4⁺ T cells, in triplicate measures, respectively, from two human donors. Error bars indicate the standard deviations (SD). Gray squares indicate romidepsin; black circles indicate panobinostat.